FibroBiologics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
FBLG Nasdaq 2830 fibrobiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FibroBiologics, Inc.

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - May 11th, 2026 6:30 am
FibroBiologics CEO Issues Letter to Shareholders - May 5th, 2026 6:30 am
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring - May 4th, 2026 2:01 pm
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - May 4th, 2026 6:30 am
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update - Apr 30th, 2026 3:55 pm
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 - Apr 30th, 2026 6:30 am
FibroBiologics Compliant with All Nasdaq Listing Requirements - Apr 20th, 2026 2:01 pm
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity - Apr 10th, 2026 6:30 am
FibroBiologics Announces Closing of $3 Million Public Offering - Apr 2nd, 2026 2:01 pm
FBLG: Advancing Fibroblast Therapy on Multiple Fronts - Apr 1st, 2026 5:40 am
FibroBiologics Announces Pricing of $3 Million Public Offering - Mar 31st, 2026 6:00 pm
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial - Mar 31st, 2026 2:15 pm
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement - Mar 25th, 2026 2:30 pm
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology - Mar 12th, 2026 6:30 am
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Mar 5th, 2026 6:30 am
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - Mar 2nd, 2026 6:30 am
FBLG: Ready to Transition to Clinical-Stage Company - Feb 27th, 2026 5:33 am
FibroBiologics to Present at the BIO Investment & Growth Summit - Feb 26th, 2026 6:30 am
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update - Feb 24th, 2026 2:30 pm
FibroBiologics Granted Extension by Nasdaq to Regain Compliance - Feb 23rd, 2026 6:30 am